BACKGROUND:Tuberculosis (TB) preventive therapy is not effective in human immunodeficiency virus (HIV) infected adults with negative tuberculin skin tests (TSTs). However, there are insufficient data on patients with advanced HIV disease from high TB incidence areas. METHODS: We conducted a randomised, double-blind, controlled trial comparing isoniazid (INH) with placebo among TST-negative adults with World Health Organization Stage 3 or 4 HIV disease. INH/placebo was administered for 12 months by patient-nominated supervisors. TST-positive participants were given open-label INH. Participants, who did not have access to antiretroviral therapy (ART), were followed up for 24 months with 6-monthly sputum culture and chest radiography. RESULTS: A total of 118 participants were enrolled: TST was negative in 98. In the randomised arms, the incidence of TB was 18/100 person-years (py) in the INH arm and 11.6/100 py in the placebo arm (hazard ratio 1.59, 95%CI 0.57-4.49). There were no significant differences in mortality, hospitalisation rate or CD4+ lymphocyte decline. INH/placebo adherence was 85%, and was significantly higher among participants with work-based treatment supervisors. CONCLUSIONS: We did not find any association between INH preventive therapy and reductions in incident TB among TST-negative adults with advanced HIV disease, but the study had limited statistical power. High levels of adherence were observed with patient-nominated supervisors.
RCT Entities:
BACKGROUND:Tuberculosis (TB) preventive therapy is not effective in human immunodeficiency virus (HIV) infected adults with negative tuberculin skin tests (TSTs). However, there are insufficient data on patients with advanced HIV disease from high TB incidence areas. METHODS: We conducted a randomised, double-blind, controlled trial comparing isoniazid (INH) with placebo among TST-negative adults with World Health Organization Stage 3 or 4 HIV disease. INH/placebo was administered for 12 months by patient-nominated supervisors. TST-positive participants were given open-label INH. Participants, who did not have access to antiretroviral therapy (ART), were followed up for 24 months with 6-monthly sputum culture and chest radiography. RESULTS: A total of 118 participants were enrolled: TST was negative in 98. In the randomised arms, the incidence of TB was 18/100 person-years (py) in the INH arm and 11.6/100 py in the placebo arm (hazard ratio 1.59, 95%CI 0.57-4.49). There were no significant differences in mortality, hospitalisation rate or CD4+ lymphocyte decline. INH/placebo adherence was 85%, and was significantly higher among participants with work-based treatment supervisors. CONCLUSIONS: We did not find any association between INH preventive therapy and reductions in incident TB among TST-negative adults with advanced HIV disease, but the study had limited statistical power. High levels of adherence were observed with patient-nominated supervisors.
Authors: Krishna P Reddy; Mark F Brady; Robert H Gilman; Jorge Coronel; Marcos Navincopa; Eduardo Ticona; Gonzalo Chavez; Eduardo Sánchez; Christian Rojas; Lely Solari; Jorge Valencia; Yvett Pinedo; Carlos Benites; Jon S Friedland; David A J Moore Journal: Clin Infect Dis Date: 2010-04-01 Impact factor: 9.079
Authors: Mercedes Yanes-Lane; Edgar Ortiz-Brizuela; Jonathon R Campbell; Andrea Benedetti; Gavin Churchyard; Olivia Oxlade; Dick Menzies Journal: PLoS Med Date: 2021-09-14 Impact factor: 11.613
Authors: Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap Journal: MMWR Recomm Rep Date: 2020-02-14
Authors: Mulugeta Russom; Henok G Woldu; Araia Berhane; Daniel Y B Jeannetot; Bruno H Stricker; Katia Verhamme Journal: Infect Dis Ther Date: 2022-01-29
Authors: Stanzi M le Roux; Mark F Cotton; Jonathan E Golub; David M le Roux; Lesley Workman; Heather J Zar Journal: BMC Med Date: 2009-11-03 Impact factor: 8.775